ATE489093T1 - Heilmittel für hyperlipidämie - Google Patents

Heilmittel für hyperlipidämie

Info

Publication number
ATE489093T1
ATE489093T1 AT05777087T AT05777087T ATE489093T1 AT E489093 T1 ATE489093 T1 AT E489093T1 AT 05777087 T AT05777087 T AT 05777087T AT 05777087 T AT05777087 T AT 05777087T AT E489093 T1 ATE489093 T1 AT E489093T1
Authority
AT
Austria
Prior art keywords
remedies
hyperlipidemia
pitavastatin
ezetimibe
hyperlipemia
Prior art date
Application number
AT05777087T
Other languages
English (en)
Inventor
Taro Aoki
Hiroyuki Yamazaki
Takashi Maejima
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35944235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE489093(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Application granted granted Critical
Publication of ATE489093T1 publication Critical patent/ATE489093T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
AT05777087T 2004-08-31 2005-08-30 Heilmittel für hyperlipidämie ATE489093T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60552504P 2004-08-31 2004-08-31
US10/997,878 US20060046996A1 (en) 2004-08-31 2004-11-29 Method for treating hyperlipidemia
PCT/JP2005/015756 WO2006025378A1 (ja) 2004-08-31 2005-08-30 高脂血症治療剤

Publications (1)

Publication Number Publication Date
ATE489093T1 true ATE489093T1 (de) 2010-12-15

Family

ID=35944235

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05777087T ATE489093T1 (de) 2004-08-31 2005-08-30 Heilmittel für hyperlipidämie

Country Status (12)

Country Link
US (2) US20060046996A1 (de)
EP (1) EP1785137B1 (de)
JP (1) JP4886516B2 (de)
KR (1) KR101244508B1 (de)
CN (1) CN101010080B (de)
AT (1) ATE489093T1 (de)
CY (1) CY1111150T1 (de)
DE (1) DE602005024981D1 (de)
ES (1) ES2354366T3 (de)
PL (1) PL1785137T3 (de)
PT (1) PT1785137E (de)
WO (1) WO2006025378A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
WO2004091660A1 (ja) * 2003-04-17 2004-10-28 Kowa Co., Ltd. Lklf/klf2遺伝子発現促進剤
ATE485267T1 (de) * 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057072A1 (es) * 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US20130023513A1 (en) * 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
JPWO2020178878A1 (de) * 2019-03-01 2020-09-10
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
PT4566591T (pt) 2023-12-07 2026-03-20 Krka D D Novo Mesto Forma de dosagem farmacêutica sólida compreendendo ezetimiba e pitavastatina

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854259A (en) * 1987-08-20 1998-12-29 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
US5185328A (en) * 1987-08-20 1993-02-09 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6465477B1 (en) * 1997-08-18 2002-10-15 Kowa Company, Ltd. Stable pharmaceutical composition
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2006204334B2 (en) * 2005-01-10 2012-02-23 Cortendo Ab (Publ) Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Also Published As

Publication number Publication date
DE602005024981D1 (de) 2011-01-05
US7459447B2 (en) 2008-12-02
PT1785137E (pt) 2010-12-23
JP4886516B2 (ja) 2012-02-29
CN101010080B (zh) 2011-02-09
ES2354366T3 (es) 2011-03-14
EP1785137A1 (de) 2007-05-16
EP1785137A4 (de) 2007-12-19
CY1111150T1 (el) 2015-06-11
KR20070047766A (ko) 2007-05-07
JPWO2006025378A1 (ja) 2008-05-08
CN101010080A (zh) 2007-08-01
US20070032467A1 (en) 2007-02-08
US20060046996A1 (en) 2006-03-02
WO2006025378A1 (ja) 2006-03-09
EP1785137B1 (de) 2010-11-24
PL1785137T3 (pl) 2011-04-29
KR101244508B1 (ko) 2013-03-18
HK1110200A1 (en) 2008-07-11

Similar Documents

Publication Publication Date Title
ATE489093T1 (de) Heilmittel für hyperlipidämie
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
PT1088824E (pt) Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase
CY2019030I2 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
NO20050073L (no) Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene
BR0211810A (pt) Derivados ácido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
CO5550436A2 (es) Derivados de benzamida
WO2009005269A3 (en) Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives
CY2017014I1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
CY1112124T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια δυσλιπιδαιμιας
CY1109240T1 (el) Συνδυασμος που περιλαμβανει βαλσαρτανη, αμλοδιπινη και υδροχλωροθειαζιδιο
GT200300054A (es) Compuestos que modulan la actividad de ppar
GT200300053A (es) Compuestos que modulan la actividad de ppar
WO2006102674A3 (en) Diphenylheterocycle cholesterol absorption inhibitors
PL1660066T3 (pl) Kompozycja farmaceutyczna zawierająca kombinację metforminy i statyny
ATE360633T1 (de) N-substituierte hydromorphone und ihre anwendung
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
BR0315580A (pt) Derivados de metileno uréia
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
LTC1725234I2 (lt) Sutrikimų arba ligų, susijusių su hiperlipidemija ir hipercholesterolemija, gydymo būdai, minimizuojant šalutinį poveikį
EP2098515A4 (de) Substituierte carbinolverbindungen
BRPI0519566A2 (pt) derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp
EA200601120A1 (ru) N-арилпиперидинзамещённые бифинилкарбоксамиды в качестве ингибиторов аполипопротеина в

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1785137

Country of ref document: EP